Propentofylline and Interleukin-4 Modulate Lesion-Associated Myeloid Responses and Improve Functional Recovery After...

Area of Science:

• Neuroscience
• Immunology
• Regenerative Medicine

Background:

• Spinal cord injury (SCI) causes secondary injury via neuroinflammation and tissue loss, hindering functional recovery.
• Current treatments for SCI struggle to address chronic inflammation and promote tissue repair effectively.

Purpose of the Study:

• To evaluate the efficacy of a combined systemic treatment of propentofylline (PPF) and interleukin-4 (IL-4) for spinal cord injury.
• To investigate the effects of PPF and IL-4 on neuroinflammation, tissue preservation, and locomotor recovery post-SCI.

Main Methods:

• In vitro studies assessed PPF's effect on IL-4-induced arginase-1 (ARG1) in microglia.
• In vivo studies in rats with contusive SCI involved daily administration of vehicle, PPF, IL-4, or combined PPF + IL-4 for 14 days.
• Locomotor function was assessed for 8 weeks, followed by histological and molecular analyses.

Main Results:

• Combined PPF + IL-4 treatment yielded superior locomotor recovery compared to monotherapy or vehicle.
• The combination therapy reduced markers of inflammation (p-p38 MAPK, pP65 NFkB), increased reparative factors (ARG1, CD206), and preserved gray/white matter.
• Significant improvements in locomotor function were observed in both male and female rats.

Conclusions:

• Systemic combination therapy with PPF and IL-4 promotes significant functional recovery after SCI.
• This treatment approach modulates neuroinflammation and enhances tissue preservation, offering a promising strategy for SCI preclinical research.